The consistent upregulation of LTF may suggest an inflamed tumor microenvironment, indicating the possibility of microbial infections and/or potentially altered iron metabolism that may contribute to subsequent resistance to systemic topotecan administration. The gene discussed is LTF; the disease is neoplasm.